
China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL
The Chinese National Medical Products Administration (NMPA) has approved tafasitamab (Minjuvi) combined with lenalidomide (Revlimid) and followed by tafasitamab monotherapy as a treatment for adult patients with relapsed or refractory diffuse large B-cell …